On August 10, the A-share medical sector continued its upward momentum! The AI medical concept led the gains, with MGI Tech Co., Ltd. surging towards the 20% daily limit, and Kingmed Diagnostics hitting the 10% daily limit. The CXO sector saw another breakout, with Porton Pharma Solutions and Pharmaron Beijing both rising over 5% further. The heavyweight leader, Wuxi Apptec Co., Ltd. (Wuxi Apptec), surged more than 7% intraday, breaking through the previous peak of the pharmaceutical bull market and setting a new all-time high! The largest medical ETF in the market, Huabao (512170), after a 4.53% surge the previous day, rose another 4% intraday, hitting a new rebound high for its price. It reclaimed the 200-day moving average after five months, with a trading volume of nearly 10 billion yuan within less than half a day.

Data shows that the underlying index of Medical ETF Huabao (512170) covers 8 CXO heavyweight stocks, with a combined weight of 32.82% as of the latest data, of which Wuxi Apptec accounts for 13.42%. On the news front, Wuxi Apptec received another significant positive catalyst! According to a filing on August 9, the U.S. court ruled on the company's motion for a preliminary injunction, challenging the 1260H designation to avoid adverse effects during the period. Last week, the company disclosed a better-than-expected half-year report: net profit attributable to shareholders exceeded 100 billion yuan for the first time in history in the first half of the year, reaching 110.8 billion yuan, a 29.43% year-on-year increase; Q2 single-quarter revenue of 165 billion yuan set a new historic high. The company raised its full-year 2026 revenue forecast to 585-605 billion yuan, with the year-on-year growth rate for continuing operations revenue raised to 35%-39%. Additionally, several overseas MNCs like Johnson & Johnson, Sanofi, Bristol-Myers Squibb, Novartis, and Roche, along with CXO companies, have recently released interim earnings reports with positive surprises and raised their full-year 2026 guidance, showing continuous improvement in CDMO and CRO orders, revenue, and profitability.

A research report from CSC Financial believes that the long-term structural opportunities in the domestic innovative drug industry have been consistently realized so far in 2026. Domestic financing continues to improve, and new drug modality tracks remain hot and are further scaling up. The new orders and performance of the domestic CRO/CDMO industry are expected to accelerate growth, driving the CXO chain into a new development phase.

To effectively participate in CXO trading, focus on two key "tools": Medical ETF Huabao (512170): The largest medical and healthcare-themed ETF in the market, focusing on medical devices (including brain-computer interfaces) + medical services (CXO content nearly 30%), while also covering the AI medical concept. For over-the-counter linked funds: 012323. Hong Kong-listed Medical ETF Huabao (159137): Heavily weighted in innovative drug chains, with 48% CXO + 20% innovative drugs, covering AI medical, medical devices (including brain-computer interfaces), and other scarce leaders in the sector. The underlying assets are Hong Kong stocks, offering high elasticity and T+0 trading. For over-the-counter linked funds: 026922.

Data sourced from the Shanghai and Shenzhen Stock Exchanges, CSI Index Company, etc. Weights data as of July 31, 2026. Institutional perspectives: Northeast Securities, July 27, 2026, "Northeast Medical & Health Weekly: Continued Optimism for Innovative Drugs and Devices as the Medium-to-Long-Term Main Line; AI Medical Has Entered a Value Realization Window." Industrial Securities, August 3, 2026, "CSC Medical Industry August 2026 Monthly Investment Report."

Note: The ETFs mentioned in the article do not charge sales service fees. Fund rates are detailed in each fund's legal documents. Risk warning: The index constituents shown in the article are for display purposes only. Descriptions of individual stocks do not constitute any form of investment advice, nor do they represent the holdings or trading intentions of any fund under the management company. The composition of the underlying index constituents is adjusted in a timely manner according to the index compilation rules. Huabao assesses the risk level of Hong Kong-listed Medical ETF Huabao and Medical ETF Huabao Linked Fund as R4-Medium to High Risk, suitable for investors with a proactive (C4) or higher risk tolerance. The risk level of Medical ETF Huabao is R3-Medium Risk, suitable for investors with a balanced (C3) or higher risk tolerance. Any information appearing in this article (including but not limited to individual stocks, comments, forecasts, charts, indicators, theories, any form of expression, etc.) is for reference only. Investors must be responsible for any investment decisions made independently. Additionally, any views, analyses, or predictions in this article do not constitute investment advice to readers in any form, nor are they responsible for any direct or indirect losses arising from the use of this article. Fund investment carries risks. Past performance of a fund does not represent its future performance. The performance of other funds managed by the fund management company does not constitute a guarantee of the fund's performance. Fund investment must be cautious. The MACD golden cross signal has formed, and these stocks are showing strong upward momentum!